LDN Treatment for Ovarian Cancer Recent Research
LDN Treatment for Ovarian Cancer Recent Research
Ovarian cancer is the leading cause of death from gynecological malignancies. Although initial therapeutic modalities are successful, 65% of these women relapse with only palliative treatments available thereafter
The following research article on PubMed concluded Low Dose Natrexone (LDN) to be a beneficial treatment option for ovarian cancer. The following results were stated:
“These preclinical data may offer a non-toxic and efficacious pathway-related treatment that can benefit patients with ovarian cancer.”
CLICK HERE to read more
Please read about the LDN Research Trust!
About LDN Research Trust
The primary aim of the Trust is to initiate Clinical Trials of Low Dose Naltrexone, help and support those who have a condition where LDN could be of benefit obtain a prescription around the world.
